Skip to main content
. 2021 Aug 24;9(9):1080. doi: 10.3390/biomedicines9091080

Figure 3.

Figure 3

Expression of SOD1* in rBM-MSCs. (A) Representative brightfield images of WT, ALS1-PreS, and ALS-EndS stem cells. Scale bar = 100 μm. (B) Growth curve of diseased and WT rBM-MSCs. Each point represents the mean of three technical replicates; * p < 0.05. (C) Representative images of Hematoxylin/Eosin (Scale bar = 50 μm) and (C’) high magnification of the ALS1-EndS stem cells. Scale bar = 20 μm. (D) Representative Western blotting analysis of naïve SOD1 and human mutant SOD1* in ALS1 and WT rBM-MSCs. (E) Densitometric analysis of the SOD1*, SOD1, and SOD1*/SOD1 ratio. (F) Representative immunofluorescences of SOD1 expression (anti-SOD1; red) and F-Actin staining (Alexa-fluor-488 Phalloidin, green); Nuclei (4′,6-diamidino-2-phenylindole, DAPI, blue), Scale bar = 20 μm. (G) Representative confocal images of immunofluorescence of SOD1 (anti-SOD1) in the rBM-MSCs cells. Scale bar = 20 μm, and (H) nuclear SOD1 fluorescence quantification. Results are reported as mean ± SD. ** p < 0.01, *** p < 0.001, **** p < 0.0001.